NIBAN3/BCNP1 抗体 (Cy5)
Quick Overview for NIBAN3/BCNP1 抗体 (Cy5) (ABIN2170585)
抗原
适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            预测反应
- Human,Mouse,Rat
- 
                                            纯化方法
- Purified by Protein A.
- 
                                            免疫原
- KLH conjugated synthetic peptide derived from huamn BCNP
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- IF(IHC-P) 1:50-200
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- 1 μg/μL
- 
                                            缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- 
                                            储存液
- Sodium azide
- 
                                            注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C
- 
                                            储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - NIBAN3/BCNP1 (Fam129c) (Family with Sequence Similarity 129, Member C (Fam129c))
- 
                                            背景
- 
                        Synonyms: B cell novel protein 1, B cell novel protein, B-cell novel protein 1, BCNP1, FAM129C, Family with sequence similarity 129, member C, Niban-like protein 2, NIBL2_HUMAN, Protein FAM129C. Background: Specifically expressed in B-lymphocytes. 
- 
                                            基因ID
- 199786
 抗原
- 
                    
 
                                     
                                     
                                    